RAMP 201
RAMP 201 produced the first approved treatment designed for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway that shrugs off chemotherapy.
In KRAS-mutant tumours, the confirmed response rate was 44% with median PFS 19.6 months and median duration of response 31.1 months; response was lower in KRAS-wild-type disease (Targeted Oncology, 2025). FDA accelerated approval 8 May 2025 for KRAS-mutated recurrent LGSOC after prior systemic therapy. The confirmatory RAMP 301 phase 3 versus chemotherapy or endocrine therapy is ongoing.
- 44 out of 100 people had their tumour shrink with Avutometinib + defactinib.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- Median 19.6 months with Avutometinib + defactinib.
- A median is a midpoint: half the people did better than this and half did worse.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Recurrent low-grade serous ovarian cancer: avutometinib (RAF/MEK clamp) + defactinib (FAK inhibitor). People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- IdeaTurn a brake back on: drugs that reactivate the PP2A phosphatase
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductMRTX1133
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductElironrasib
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- PathwayInvasion: proteases, adhesion & the invasive front
Shares Low-grade serous ovarian cancer (LGSOC), Avutometinib + defactinib, KRAS.
- CompanyQuanta Therapeutics
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- CompanyFrontier Medicines
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- TermDownstream and upstream
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.